A Phase 2, Open-label, Controlled, Multi-center Study to Evaluate Meningococcal ACWY Antibody Response in Children Aged 40 and 60 Months who Have Previously Received Novartis enACWY Conjugate Vaccine as Infants.
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2016
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal infections
- Focus Pharmacodynamics
- Sponsors Novartis Vaccines
- 26 Nov 2010 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network.
- 19 Apr 2010 New trial record